Merck News

Name Symbol Markt Aktientyp
Merck and Co Inc MRK NYSE Common Stock
  Änderung Änderung % Aktuell Zeit
-0,53 -0,51% 102,93 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
103,19 102,48 103,79 102,94 103,46
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
03.2.202322:28EDGARAmended Statement of Ownership (sc 13g/a)
03.2.202313:29DJNMerck's Keytruda Meets Main Endpoints in Endometrial..
03.2.202312:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Met..
02.2.202312:44EDGARCurrent Report Filing (8-k)
02.2.202312:30BWMerck Announces Fourth-Quarter and Full-Year 2022 Financial..
27.1.202312:45BWFDA Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment..
26.1.202314:02BWMerck Animal Health Receives U.S. FDA Approval of Expanded..
25.1.202323:35EDGARStatement of Changes in Beneficial Ownership (4)
25.1.202323:27EDGARStatement of Changes in Beneficial Ownership (4)
25.1.202323:04EDGARStatement of Changes in Beneficial Ownership (4)
25.1.202322:53EDGARStatement of Changes in Beneficial Ownership (4)
25.1.202322:42EDGARStatement of Changes in Beneficial Ownership (4)
25.1.202313:44DJNMerck Reports Keytruda Phase 3 Success, Failure
25.1.202312:50BWMerck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA®..
25.1.202312:45BWMerck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy..
24.1.202319:19BWMerck Announces Second-Quarter 2023 Dividend
18.1.202304:58PRNCAMerck Selects Perceiv AI for Inaugural Digital Sciences..
11.1.202322:23EDGARStatement of Changes in Beneficial Ownership (4)
11.1.202312:45BWMerck Completes Tender Offer to Acquire Imago BioSciences,..
10.1.202315:00BWMerck Named One of America’s Most JUST Companies by JUST..
05.1.202312:45BWMerck to Hold Fourth-Quarter and Full-Year 2022 Sales and..
03.1.202322:42EDGARStatement of Changes in Beneficial Ownership (4)
03.1.202322:36EDGARStatement of Changes in Beneficial Ownership (4)
03.1.202322:30EDGARStatement of Changes in Beneficial Ownership (4)
03.1.202312:45BWMerck to Present at the 41st Annual J.P. Morgan Healthcare..
30.12.202219:39DJNTrending: Merck's Molnupiravir Approved for Emergency Use in..
30.12.202213:33DJNChina Approves Merck's Molnupiravir for Emergency Use,..
30.12.202210:07DJNCorrection to Molnupiravir Approved in China Article
30.12.202209:39DJNChina Approves Merck's Molnupiravir for Emergency Use,..
22.12.202213:00BWMerck to Present at the Goldman Sachs Healthcare CEOs..
22.12.202212:45BWMerck and Kelun-Biotech Announce Exclusive License and..
21.12.202212:45BWLYNPARZA® (olaparib) in Combination With Abiraterone and..
20.12.202212:45PRNUSAstellas, Seagen and Merck Announce FDA Acceptance of..
15.12.202213:30DJNMerck, AstraZeneca Receive FDA Extension on Lynparza New..
15.12.202212:45BWAstraZeneca and Merck Provide Update on US Regulatory Review..
13.12.202220:33DJNTrending: Moderna, Merck Say Cancer Vaccine and Keytruda..
12.12.202212:45BWMerck Begins Tender Offer to Acquire Imago BioSciences, Inc.
09.12.202206:55TRMNSVB Securities Keeps Their Buy Rating on Merck & Company..
01.12.202212:45BWMerck to Present Data From Its Hematology Portfolio and..
29.11.202217:41BWMerck Announces First-Quarter 2023 Dividend
23.11.202208:44DJNMerck's Keytruda Hits Main Endpoint in Stomach Cancer Study
23.11.202204:35TRMNMerck & Company (MRK) Gets a Buy from SVB Securities
22.11.202212:45BWMerck Announces Phase 3 KEYNOTE-859 Trial Met Primary..
21.11.202220:35DJNTrending: Merck to Acquire Imago BioSciences for $1.35..
21.11.202216:32DJNImago BioSciences Shares Take Flight on Takeover by Merck
21.11.202214:55TRMNMizuho Securities Reaffirms Their Buy Rating on Merck &..
21.11.202213:29DJNMerck to Buy Imago for $36 A Share, More Than Double..
21.11.202212:45BWMerck to Present at the 5th Annual Evercore ISI HealthCONx..
14.11.202212:45BWLYNPARZA® (olaparib) in Combination With Abiraterone and..
10.11.202223:03EDGARStatement of Changes in Beneficial Ownership (4)
Kürzlich von Ihnen besucht
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Melden Sie sich bei ADVFN an
Jetzt registrieren

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

P: V: D:20230204 12:12:13